Prosecution Insights
Last updated: November 04, 2026
Application No. 18/935,343

USE OF CELL MEMBRANE-BOUND SIGNALING FACTORS

Non-Final OA §103§112§DOUBLEPATENT
Filed
Nov 01, 2024
Priority
Nov 16, 2016 — provisional 62/422,900 +2 more
Examiner
BERTOGLIO, VALARIE E
Art Unit
1632
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Aivita Biomedical Inc.
OA Round
1 (Non-Final)
64%
Grant Probability
Moderate
1-2
OA Rounds
1y 3m
Est. Remaining
94%
With Interview

Examiner Intelligence

Grants 64% of resolved cases
64%
Career Allowance Rate
559 granted / 873 resolved
+4.0% vs TC avg
Strong +30% interview lift
Without
With
+30.1%
Interview Lift
resolved cases with interview
Typical timeline
3y 3m
Avg Prosecution
46 currently pending
Career history
908
Total Applications
across all art units

Statute-Specific Performance

§101
4.1%
-35.9% vs TC avg
§103
26.7%
-13.3% vs TC avg
§102
15.4%
-24.6% vs TC avg
§112
41.7%
+1.7% vs TC avg
Black line = Tech Center average estimate • Based on career data from 873 resolved cases

Office Action

§103 §112 §DOUBLEPATENT
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claims 21-44 are pending and under consideration. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 21-44 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 21 is unclear because it is drawn to a producr but contains a pharase that appears to be a method step. Step c recites, “harvested from a population of stem cells using a harvesting solution”. It is not clear if this is intended to be a required step or if it intended to be a product by process type clause where the process of harvesting structurally or functionally could alter the claims product. It is also not clear if the harvesting solution is part of the claimed product. Claims 22-44 are unclear given their dependency from claim 21. Consequently, claim 30 is unclear because it limits the amount of harvesting solution in the product but the harvesting solution isn’t necessarily or clearly claimed to be present. Claim 28 is unclear as it recites that the lipid “can be”, which does not render it clear if the lipid is limited to those recited in claim 28. Claim 31 is unclear as it limits the tissue but there is not antecedent basis for “the tissue”. Claim 37 is unclear as to whether “is mixed with” is a method step or is intended to read as “further comprising”. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claims 21-44 are rejected under 35 U.S.C. 103 as being unpatentable over US 6,207,718 B1 to Papadimitriou in view of US2012/0121693 A1 to Cotsarelis et al. (hereinafter 'Cotsarelis'). Papadimitriou teaches a pharmaceutical composition comprising a complex of lipid-modified hedgehog proteins (Sonic hedgehog, Example 3; claim 24) and a cyclodextrin (col 1, ln 7-18; .beta.-cyclodextrin, Col. 3; claim 22) as a pharmaceutical excipient for delivery. “Hedgehog (hh) proteins are understood as a family of secreted signal proteins which are responsible for the formation of numerous structures in embryogenesis ... In its natural form the N-terminal domain is modified with cholesterol or palmitoyl.” Cholesterol and palmitoyl are lipids and thus the Hh protein is lipid modified, as claimed. The Abstract states, “A composition of a hedgehog protein which includes as an additive cyclodextrin, a non-ionic detergent, an anionic saccharide and/or ionic salt ... is especially stable at room temperature.” "The compositions described herein are also particularly suitable for producing carrier matrices containing a pharmaceutically effective amount of hedgehog protein. The carrier matrices ... can be administered to a human patient to provide delayed release of pharmaceutically effective hedgehog protein in the human body' (col 2, ln 29-36). Papadimitriou also discusses that the Hh can be made more hydrophobic by palmitoylation (chemically modified and palmitate, claims 23 and 28, respectively). Papadimitriou discusses that as a pharmaceutical, the composition is preferable aqueous (claim 41) at a pH of 5-8 (claim 42) and can contain an antibiotic (claim 43) or trehalose (claim 44). See column 5. Papadimitriou does not teach inclusion of a lipid-modified Wnt in the Shh-cyclodextrin composition. However, Cotsarelis teaches a method of promoting tissue regeneration in a tissue in need thereof, comprising exposing a tissue to a composition comprising a hedgehog protein and/or a Wnt protein, wherein the composition is formulated as a cream or ointment (see para 60; claim 29) “The present invention provides methods of treating baldness in a subject and generating new hair follicles, comprising epidermal disruption and administration of a compound that promotes a differentiation of an uncommitted epidermal cell into a hair follicle cell.' (Abstract). Cotsarelis claims “A method for generating a hair follicle in a scalp, eyebrow, or scarred region of a subject, the method comprising the steps of…. (b) contacting said scalp, eyebrow, or scarred region with a compound or factor that promotes a differentiation of an uncommitted epidermal cell into a hair follicle cell, thereby generating a hair follicle….” (claim 1). The compounds include Wnt and shh (Hh). Claim 11 of Cotsarelis limits the compound to Wnt7 (claim 25). Claim 17 limits the compound or factor to hedgehog. See also paragraphs 19,38 and 98. Paragraph 98 teaches the combination of Wnt and Hh. Claims 31 and 32 unclear in limiting “the tissue” because there is not tissue as part of the claimed composition. However, to the extent that Cotsarelis teaches applying the composition to a hair follicle, claims 31-32 are included in this rejection. The composition is topical (claim 40). It would have been obvious to one of ordinary skill in the art at the time of filing combine 1) the composition of lipid-modified hedgehog protein and a cyclodextrin of Papadimitriou in the method of using 2) a combination of Hedgehog protein and a Wnt protein for hair growth of Cotsarelis that would result in the formation of a cyclodextrin molecule conjugated to lipid-modified hedgehog (Papadimitriou) and Wnt (Cotsarelis), as claimed. One would have been motivated to make such a combination because Papadimitriou taught the cyclodextrin complexed, lipid-modified Shh protein is stable at room temperature and time-released. One would have a reasonable expectation of success because the requisite knowledge and skills for combining the compounds was well-known and routine. With regard to claims 22, Papadimitriou teaches b-cyclodextrin at col. 3, lines 32-34. With regard to claim 24, Papadimitriou teaches sonic, desert and indian hedgehog. Cotsarelis teaches numerous Wnts including Wnt 3a (claim 25). With regard to claim 26-27 and 34-36, the wherein clause amounts to a product by process type of limitation where the method of obtaining the protein is given little patentable weight when it is not shown to substantively change the product. It is held that Hh proteins isolated from stem cells are not substantively different from Hh proteins isolated from non-stem cells. With regard to claim 30, not only is it not clear that the harvesting solution is part the claimed product of claim 21, the composition of the solution is entirely undefined. Thus, for compact prosecution, claim 21 is included to t he extent that any solution that the composition comprises can be considered “harvesting solution”. With regard to claim 37, Cotsarelis discusses pharmaceutically acceptable carriers, which are excipients at para 182. With regard to claim 38, there is no teaching that fails to meet the negative limitation “wherein the…protein are not treated with detergent or an organic solvent”. With regard to claim 39, the claims do not require the harvest solution be present in the composition but limit the concentration of the cyclodextrin in the solution used to harvest the composition. This appears to be a product by process limitation that does not necessarily affect the characteristics of the harvested product. Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. Claims 21-29,31-44 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-20 of U.S. Patent No. 11,666,522. Although the claims at issue are not identical, they are not patentably distinct from each other because the patented claims are drawn to methods of making the currently claimed product, which renders the product obvious. Trehalose of instant claim 44 is recited in patent claim 4. The excipient of claim 37 is recited in patent claim 2. The antimicrobial of claim 43 is recited in patent claim 13. The hedgehog proteins of claim 24 are recited in patent claim 14. The wnts of claim 25 are recited in patent claim 15. The stem cells of claims 26,34-35 are recited in patent claim 16. The tissues of claim 31 are recited in patent claim 20. The genetically engineered limitation of claim 27 is recited in patent claim 18. Claims 21-29,31-44 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-17 of U.S. Patent No. 12268770. Although the claims at issue are not identical, they are not patentably distinct from each other because the patented claims are drawn to methods of using the currently claimed product, which renders the product obvious. Trehalose of instant claim 44 is recited in patent claim 4. The cyclodextrins of claim 22 is recited in patent claim 2. The lipids of claim 28 are recited in patent claim 8. The antimicrobial of claim 43 is recited in patent claim 13. The hedgehog proteins of claim 24 are recited in patent claim 4. The wnts of claim 25 are recited in patent claim 5. The stem cells of claims 26,34-36 are recited in patent claim 6,14-16. The tissues of claim 31 are recited in patent claim 11. The genetically engineered limitation of claim 27 is recited in patent claim 7. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to VALARIE BERTOGLIO whose telephone number is (571)272-0725. The examiner can normally be reached on M-F 6AM-2:30PM. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Peter Paras can be reached on 571-272-4517. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see https://ppair-my.uspto.gov/pair/PrivatePair. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /VALARIE E BERTOGLIO/Primary Examiner, Art Unit 1632
Read full office action

Prosecution Timeline

Nov 01, 2024
Application Filed
May 18, 2026
Response after Non-Final Action
Oct 30, 2026
Non-Final Rejection mailed — §103, §112, §DOUBLEPATENT (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12778983
METHODS OF PRODUCING HUMAN RPE CELLS AND PHARMACEUTICAL PREPARATIONS OF HUMAN RPE CELLS
2y 12m to grant Granted Nov 03, 2026
Patent 12766199
GENE THERAPY VECTORS FOR TREATING HEART DISEASE
3y 2m to grant Granted Oct 20, 2026
Patent 12767930
Method For Promoting Differentiation Of Pluripotent Stem Cells By Reducing Undifferentiated State Thereof
2y 2m to grant Granted Oct 20, 2026
Patent 12760271
MIDBRAIN DOPAMINE (DA) NEURONS FOR ENGRAFTMENT
2y 7m to grant Granted Oct 13, 2026
Patent 12747278
CHIMERIC ANTIGEN RECEPTOR FOR TREATMENT OF CANCER
3y 10m to grant Granted Sep 29, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
64%
Grant Probability
94%
With Interview (+30.1%)
3y 3m (~1y 3m remaining)
Median Time to Grant
Low
PTA Risk
Based on 873 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month